Drug Discovery World

MARCH 13, 2023

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The post LEO partners with ICON to offer patient-centric dermatology trials appeared first on Drug Discovery World (DDW).

Trials 130

Trials Clinical Trials Laboratories Clinical Development 130

Drug Discovery World

APRIL 11, 2024

Biopharmaceutical company EpiEndo has completed a Phase IIA clinical trial for its therapy addressing chronic obstructive pulmonary disease (COPD). COPD currently has limited treatment options despite being a leading cause of death globally. By 2030, it’s estimated that the global cost of COPD will rise to $4.8

Therapies 130

Therapies Clinical Trials Disease Trials 130

Drug Discovery World

AUGUST 2, 2024

GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. of subjects achieving LFC normalisation after 12 weeks of treatment. relative reduction in liver fat content (LFC), with up to 55.6%

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Discovery World

APRIL 14, 2023

The headlines our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. There is also new hope for sepsis treatment and for preventing cardiovascular disease in people with HIV thanks to recent research.

Vaccine 130

Vaccine Clinical Trials Drugs Pharmaceutical Companies 130

Drug Discovery World

OCTOBER 18, 2023

We’re beginning to see their potential come to fruition, with the FDA having approved three treatments as of January 2023 — for retinal dystrophy 1 spinal muscular atrophy, 2 and haemophilia B. 4 Unfortunately, many AAV-based gene therapies fail during clinical trials, despite them appearing safe and efficacious in preclinical studies.

Therapies 162

Therapies Clinical Trials FDA Approval Virus 162

Drug Discovery World

DECEMBER 7, 2023

The whitepaper ‘Guiding principles for drug discovery and development in amyotrophic lateral sclerosis’ outlines a consensus-based approach to de-risk clinical trials of novel therapeutics by an enhanced evidenced-based approach to pre-clinical studies. The Guiding Principles underpin a new £5 ($6.2)

Bioinformatics 130

Bioinformatics Drugs Clinical Trials Trials 130

Drug Discovery World

MAY 22, 2023

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease.

Disease 130

Disease Clinical Trials Laboratories Treatment 130

Drug Discovery World

MARCH 2, 2023

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in targeted treatments for cancer and asked what advances the future might bring. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

JULY 31, 2023

Despite a range of treatments for heart failure, Dr Streefkerk argues that there are still a lot of patients dying or ending up in hospital due to the condition. But despite high levels of research, treatments are still limited and surgical interventions are commonplace for many heart conditions. million people every year.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

The Pharma Data

NOVEMBER 1, 2020

The trial is expected to enroll 160 patients. billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies.

Clinical Trials 52

Clinical Trials FDA Trials Treatment 52

FDA Law Blog: Biosimilars

JULY 10, 2024

Lenz, Principal Medical Device Regulation Expert — FDA’s Center for Devices and Radiological Health (CDRH) recently partnered with the Digital Medicine Society (DiMe) to host a two-day workshop to help advance the use of patient-generated health data (PGHD) to support improved clinical trials, medical device development, and regulatory science.

Clinical Trials 59

Clinical Trials Regulations Trials Treatment 59

Vial

MAY 20, 2024

Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

Drug Target Review

SEPTEMBER 21, 2023

The findings supported the possibility put forward by Cotton et al (2016) concerning the chance of repurposing these drugs for adulticidal treatment. The available treatment for that is minor surgery -to remove the nodules. With accessible and effective treatments, this is feasible. doi: 10.1002/14651858.CD011146.pub2.

Drugs 105

Drugs Treatment Disease Research 105

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments.

Drugs 130

Drugs Engineering Clinical Trials Science 130

Drug Discovery World

JANUARY 2, 2024

As for Infinitopes, the company’s trials will begin in 2024. He said: “Between now and 2030, we’re going to see a range of vaccines using various technologies. However, she believes perhaps the biggest issue with treatment development is simply: it takes too long. She said: “The speed is not sustainable.

Research 147

Research Vaccine Science Trials 147

DrugBank

MARCH 7, 2024

adults using obesity medications by 2030, further underlining the growing significance of this sector. Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Goldman Sachs analysts anticipate a significant rise in the number of U.S.

Pharmaceutical Companies 82

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 82

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Clinical Trials Therapies Disease 52

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. With sales soaring to $2.2 for this class of drugs.

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 69

Drug Discovery World

AUGUST 14, 2023

These advanced therapies are revolutionising treatment options and opening new avenues for targeted and individualised healthcare, offering tremendous promise to patients worldwide, including those living with life-threatening or debilitating diseases. By 2030, it’s expected to more than double, to $34.3 billion in 2020 to $15.5

Marketing 130

Marketing DNA Therapies FDA 130

Drug Discovery World

APRIL 10, 2024

An ICON survey of over 100 drug development professionals in obesity research revealed optimism about future therapies, with a significant shift towards combination treatments for obesity and its comorbidities.

Clinical Trials 130

Clinical Trials Trials Therapies Treatment 130

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). Learnedness from these studies have been incorporated into the optimised design of two ongoing parallel, global, placebo- controlled and randomised Phase III trials, GRADUATE 1 and 2. trillion per space by 2030.

Disease 52

Disease FDA Therapies Testimonials 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Therapies 40

Therapies Trials Treatment Disease 40

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. However, because these trials come with a significant financial burden, sponsor companies are constantly seeking ways to optimize their operations.

Clinical Trials 52

Clinical Trials Trials International Compliance 52

The Pharma Data

JUNE 28, 2021

The company’s Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic AD. The trial enrolled 272 patients who were selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by PET imaging.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies.

Disease 52

Disease Therapies FDA Trials 52

The Pharma Data

MARCH 13, 2021

Donanemab has the potential to become a very important treatment for Alzheimer’s disease. ” Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. Apostolova, M.D., percent), nausea (10.7

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

NOVEMBER 6, 2021

Abbott (NYSE ABT) moment blazoned the launch of a new action designed to help produce a further inclusive clinical trial ecosystem through new approaches to training, education, and perfecting the clinical exploration structure within theU.S. People of different ethnical and artistic backgrounds make up nearly 40 of theU.S.

Clinical Trials 52

Clinical Trials Research Trials International 52

Drug Discovery World

JULY 11, 2022

The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1. These challenges exist across the translation cycle from early research to clinical trials, manufacturing, and ultimately reimbursement. Regulatory requirements.

Therapies 130

Therapies Clinical Trials Production Trials 130

Vial

FEBRUARY 15, 2024

Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030).

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

The Pharma Data

FEBRUARY 21, 2022

The company is advancing around 50 projects in ongoing clinical trials across a range of potential therapeutic modalities and indications, with a focus on oncology, cardiovascular and women’s health. Strong pipeline with robust late-stage development program and broad potential across indications. “We

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

JULY 29, 2021

P-tau217 in blood showed promise as additional biomarker of efficacy- Donanemab treatment led to 24% lowering of P-tau217 from baseline. Visit LillyMemoryTrials.com for additional information on enrolling in Alzheimer’s disease trials. In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020.

Disease 52

Disease Pharmacokinetics Treatment FDA 52

The Pharma Data

MARCH 9, 2021

Lilly will present detailed results of the TRAILBLAZER-ALZ phase 2 study, which showed that donanemab treatment resulted in significant slowing of decline in a composite measure of cognition and daily function in people with early symptomatic Alzheimer’s disease (AD) compared to placebo. . About Avid Radiopharmaceuticals.

Disease 40

Disease International Research Therapies 40

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

The Pharma Data

MAY 4, 2021

This donation furthers both Lilly and Direct Relief’s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries. Baricitinib has not been approved for the treatment of COVID-19, but has been authorized for emergency use by the FDA.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

Drug Discovery World

FEBRUARY 10, 2023

This is reflected in the government’s aim of becoming a leader in the ATMP space by 2030. Magnus Persson is a physician and scientist with a background in both academia and industry, working for the likes of Sanofi on clinical trials activities and across venture capital firms in the US.

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

DrugBank

AUGUST 9, 2024

Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. However, searching for broader applicability and personalized approaches continues, as not all patients respond to these treatments. billion by 2030.

Pharmaceuticals 78

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 78